Cargando…

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)

BACKGROUND: Data from recent cardiovascular outcome trials in patients with type 2 diabetes (T2D) suggest that sodium-glucose cotransporter 2 (SGLT2) inhibitors can prevent development of heart failure (HF) and prolong life in patients without HF. Ongoing event-driven trials are investigating whethe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Jesper, Omar, Massar, Kistorp, Caroline, Poulsen, Mikael Kjær, Tuxen, Christian, Gustafsson, Ida, Køber, Lars, Gustafsson, Finn, Fosbøl, Emil, Bruun, Niels Eske, Videbæk, Lars, Frederiksen, Peter Hartmund, Møller, Jacob Eifer, Schou, Morten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588901/ https://www.ncbi.nlm.nih.gov/pubmed/31227014 http://dx.doi.org/10.1186/s13063-019-3474-5

Ejemplares similares

The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)
por: Omar, Massar, et al.
Publicado: (2022)

Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial
por: Jürgens, Mikkel, et al.
Publicado: (2021)

Two Decades of Cardiac Amyloidosis: A Danish Nationwide Study
por: Westin, Oscar, et al.
Publicado: (2021)

Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial)
por: Jürgens, Mikkel, et al.
Publicado: (2019)

Specialized heart failure clinics versus primary care: Extended registry-based follow-up of the NorthStar trial
por: Malmborg, Morten, et al.
Publicado: (2023)

Identification of Patients with New-Onset Heart Failure and Reduced Ejection Fraction in Danish Administrative Registers
por: Madelaire, Christian, et al.
Publicado: (2020)

Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve
por: Holmager, Pernille, et al.
Publicado: (2017)

A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)
por: Jorsal, Anders, et al.
Publicado: (2014)

Occult cardiac amyloidosis?
por: Westin, Oscar, et al.
Publicado: (2019)

ODP154 Reduction of Cardiac Adipose Tissue Volume with Short-Term Empagliflozin in Patients with Type 2 Diabetes: Results from the SIMPLE Randomized Clinical Trial
por: Brandt-Jacobsen, Niels, et al.
Publicado: (2022)

Renal dysfunction, restrictive left ventricular filling pattern and mortality risk in patients admitted with heart failure: a 7-year follow-up study
por: Schou, Morten, et al.
Publicado: (2013)

Renal function at the time of a myocardial infarction maintains prognostic value for more than 10 years
por: Kümler, Thomas, et al.
Publicado: (2011)

Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial
por: Brandt‐Jacobsen, Niels H., et al.
Publicado: (2023)

Temporal trends in the incidence of infective endocarditis in patients with a prosthetic heart valve
por: Hadji-Turdeghal, Katra, et al.
Publicado: (2023)

The association of prior carpal tunnel syndrome surgery with adverse cardiovascular outcomes and long-term mortality after aortic valve replacement
por: Westin, Oscar, et al.
Publicado: (2021)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Impact of first-time detected atrial fibrillation after transcatheter aortic valve replacement: A nationwide study
por: Petersen, Jeppe Kofoed, et al.
Publicado: (2023)

Characteristics and long‐term prognosis of patients with heart failure and mid‐range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta‐analysis
por: Lauritsen, Josephine, et al.
Publicado: (2018)

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
por: Lee, Matthew M.Y., et al.
Publicado: (2020)

Differences in mortality in patients undergoing surgery for infective endocarditis according to age and valvular surgery
por: Østergaard, Lauge, et al.
Publicado: (2020)

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
por: Dewan, Pooja, et al.
Publicado: (2021)

Optimal Cardiac Resynchronization Therapy Pacing Rate in Non-Ischemic Heart Failure Patients: A Randomized Crossover Pilot Trial
por: Ghotbi, Adam Ali, et al.
Publicado: (2015)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Troponin dependent 30-day mortality in patients with acute pulmonary embolism
por: Sonne-Holm, Emilie, et al.
Publicado: (2023)

Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study
por: Rasmussen, Jon Jarløv, et al.
Publicado: (2016)

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction
por: Cannon, Jane A., et al.
Publicado: (2016)

Conversion of abstract to peer-reviewed publication at the European Society of Cardiology Congress Young Investigator Award: a comparison of winners and non-winners
por: Søndergaard, Matthias, et al.
Publicado: (2023)

Diuretic treatment before and after transcatheter aortic valve implantation: A Danish nationwide study
por: Begun, Xenia, et al.
Publicado: (2023)

Temporal Changes, Patient Characteristics, and Mortality, According to Microbiological Cause of Infective Endocarditis: A Nationwide Study
por: Østergaard, Lauge, et al.
Publicado: (2022)

Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure
por: Stoltze Gaborit, Freja, et al.
Publicado: (2016)

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF
por: Adamson, Carly, et al.
Publicado: (2022)

Recurrence of bacteremia and infective endocarditis according to bacterial species of index endocarditis episode
por: Østergaard, Lauge, et al.
Publicado: (2023)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction
por: Jensen, Jesper, et al.
Publicado: (2020)

Temporal changes in cardiovascular disease and infections in dialysis across a 22-year period: a nationwide study
por: Kaur, Kamal Preet, et al.
Publicado: (2021)

Prognostic utility of diastolic dysfunction and speckle tracking echocardiography in heart failure with reduced ejection fraction
por: Hansen, Sune, et al.
Publicado: (2019)

Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction
por: Vishram-Nielsen, Julie K. K., et al.
Publicado: (2022)

Pressure–flow responses to exercise in aortic stenosis, mitral regurgitation and diastolic dysfunction
por: Andersen, Mads J, et al.
Publicado: (2022)

Incidence of thyroid dysfunction following initiation of amiodarone treatment in patients with and without heart failure: a nationwide cohort study
por: Ali, Sam Aiyad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6t9l6hosf82n4q3rdskn1g2okf